Genetic Polymorphism oriented PhaseI Study of Irinotecan and Doxifluridine for Unresectable or Recurrent Colorectal Cancer.

Trial Profile

Genetic Polymorphism oriented PhaseI Study of Irinotecan and Doxifluridine for Unresectable or Recurrent Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Doxifluridine (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2009 Status changed from not stated to active, no longer recruiting.
    • 26 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top